contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …

contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …

I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I …-2006. The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer …

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I …-2006. The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer …

We analyze the association that pharmaceutical innovation had with premature mortality from all diseases in Switzerland … 2002-2019. The analysis is performed by investigating whether the diseases that experienced more pharmaceutical innovation … had larger subsequent declines in premature mortality and hospitalization. Pharmaceutical innovation is measured by the …

U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual data are available … for only one type of innovation new drugs but pharmaceutical R&D accounts for a significant fraction of total biomedical … research. The empirical analysis provides strong support for the hypothesis that both medical innovation (in the form of new …